beta-Cubebene is a woody-spicy sesquiterpene hydrocarbon associated with cubeb, juniper, and other spice- or leaf-oriented essential-oil profiles. In the current research pass, the strongest evidence is identity, occurrence, and biosynthetic context rather than standalone human-use or safety data. A few papers report beta-cubebene as a major component in bioactive essential oils, and one plant-biochemistry study shows terpene-synthase formation of beta-cubebene from farnesyl diphosphate, but direct isolated pharmacology remains sparse. For AromaForge, this makes beta-cubebene a useful composition marker with explicit evidence gaps.
Chemical identity and composition
PubChem lists beta-cubebene as C15H24 with tricyclic sesquiterpene structure data and CAS 13744-15-5. Within the AromaForge archive it already appears in juniper whole oil at 2.8%, supporting use as a real archive constituent rather than a speculative synonym. The public literature also documents beta-cubebene as a recurrent major-to-mid-level component in several volatile-oil studies.
Aroma and practical use
- Use the recorded woody, dry, spicy, terpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2008 Plant Physiology study reported that recombinant Magnolia grandiflora terpene synthase Mg25 converted farnesyl diphosphate predominantly to beta-cubebene, directly linking the constituent to characterized plant sesquiterpene biosynthesis.
A 2008 Plant Physiology study reported that recombinant Magnolia grandiflora terpene synthase Mg25 converted farnesyl diphosphate predominantly to beta-cubebene, directly linking the constituent to characterized plant sesquiterpene biosynthesis.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2015 Molecules paper on Xanthium strumarium essential oil identified beta-cubebene at 3.8% and reported antimicrobial and antioxidant activity for the oil, but the activity was not isolated to beta-cubebene alone.
A 2015 Molecules paper on Xanthium strumarium essential oil identified beta-cubebene at 3.8% and reported antimicrobial and antioxidant activity for the oil, but the activity was not isolated to beta-cubebene alone.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2002 Phytochemistry paper on Solidago canadensis described 6-epi-beta-cubebene as a major constituent and beta-cubebene as a minor constituent, reinforcing the cubebane structural family context but not providing direct human-use evidence.
A 2002 Phytochemistry paper on Solidago canadensis described 6-epi-beta-cubebene as a major constituent and beta-cubebene as a minor constituent, reinforcing the cubebane structural family context but not providing direct human-use evidence.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No authoritative constituent-specific dermal limit, RIFM review, or human tolerability study was verified for isolated beta-cubebene in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the accessible activity literature is mostly mixture-level and not isolate-level, archive copy should avoid attributing antimicrobial or other wellness effects directly to beta-cubebene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
terpene synthase formation from fpp
In Magnolia grandiflora, a recombinant terpene synthase designated Mg25 converted farnesyl diphosphate predominantly to beta-cubebene, giving the strongest source-grounded mechanistic context located in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Direct isolate-level pharmacology for beta-cubebene was sparse in the reviewed public literature.
- No human clinical evidence for isolated beta-cubebene was verified in this pass.
- Public constituent-specific safety assessment data remain thin.
- 2026-07-13 verification pass: confirmed no individual IFRA Standard exists for beta-cubebene (full-text search of IFRA 51st Amendment, keyword 'cubebene', no match) and no Tisserand & Young Essential Oil Safety monograph or EU Cosmetics Regulation Annex III listing was located. The prior dermal_limit_pct (25%) and sensitizing (true) values had no supporting citation and are corrected to null/unknown rather than presented as sourced facts.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.